A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer

Clinical Cancer Research

Volumn 5, Issue 8, 1999, Pages 1989-1995

  Bhargava, Pankaj ^a   Marshall, John L ^a   Rizvi, Naiyer ^a   Dahut, William ^a   Yoe, Joseph ^a   Figuera, Manuela ^a   Phipps, Kim ^a   Ong, Voon S ^b   Kato, Allen ^b   Hawkins, Michael J ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FUMAGILLOL CHLOROACETYLCARBAMATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VERTIGO;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM; CEREBELLAR ATAXIA; CONFUSION; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SESQUITERPENES; VERTIGO;

EID: 6544276582     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Folkman, J., and Klagsburn, M. Angiogenic factors. Science (Washington DC), 235: 442-447, 1987.
2. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
3. Denekamp, J., and Hobson, B. Endothelial-cell proliferation in experimental tumours. Br. J. Cancer, 46: 711-720, 1982.
4. Hirst, D. G., Denekamp, J., and Hobson, B. Proliferation kinetics of endothelial and tumour cells in three mouse mammary carcinomas. Cell Tissue Kinet., 15: 251-261, 1982.
5. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 590: 404-407, 1997.
6. Hanson, F., and Eble, T. An antiphage agent isolated from aspergillus sp. J. Bacteriol., 58: 527-529, 1949.
7. McCowen, M., Callender, M., and Lawalis, J, Jr. Fumagillin (H-3), a new antibiotic with amebicidal properties. Science (Washington DC), 113: 202-203, 1951.
8. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (Lond.), 348: 555-557, 1990.
9. Kusaka, M., Sudo, K., Matsutani, E., Kozai, Y., Marui, S., Fujita, T., Ingber, D., and Folkman, J. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br. J. Cancer, 69: 212-216, 1994.
10. Kusaka, M., Sudo, K., Fujita, T., Marui, S., Itoh, F., Ingber, D., and Folkman, J. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem. Biophys. Res. Commun., 174: 1070-1076, 1991.
11. Yamaoka, M., Yamamoto, T., Ikeyama, S., Sudo, K., and Fujita, T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res., 55: 5233-5236, 1993.
12. Yanase, T., Tamura, M., Fujita, K., Kodama, S., and Tanaka, K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res., 55: 2566-2570, 1993.
13. Takamiya, Y., Brem, H., Ojeifo, J., Mineta, T., and Martuza, R. L. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery, 34: 869-875, 1994.
14. Takamiya, Y., Friedlander, R. M., Brem, H., Malick, A., and Martuza, R. L. Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470. J. Neurosurg., 78: 470-476, 1993.
15. Sin, N., Meng, L., Wang, M. Q., Wen, J. J., Bornmann, W. G., and Crews, C. M. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, metap-2. Proc. Natl. Acad. Sci. USA, 94: 6099-6103, 1997.
16. Pluda, J., Wyvill, K., Figg, W. D., Whitcup, S., Lietzau, S., Saville, M., Cohen, R., Feigal, E., Parks, D., Foli, A., Bailey, S., Broder, S., and Yarchoan, R. A Phase I study of angiogenesis inhibitor, TNP-470 (AGM-1470), administered to patients with HIV-associated Kaposi's sarcoma. Proc. Am. Soc. Clin. Oncol, 57: A8, 1994.
17. Kudelka, A., Levy, T., Verschraegen, C., Edwards, C., Piamsomboon, S., Termrungruanglert, W., Freedman, R., Kaplan, A., Kieback, D., Meyers, C., Jaeckle, K., Loyer, E., Steger, M., Mante, R., Mavligit, G., Killian, A., Tang, R., Gutterman, J. U., and Kavanagh, J. A Phase I trial of TNP-470 administered to patients with advanced squamous cell carcinoma of the cervix. Clin. Cancer Res., 3: 1502-1505, 1997.
18. Milkowski, D., and Weiss, R. TNP-470. In: B. Teicher (ed.), Antiangiogenic Agents in Cancer Therapy. Totowa, NJ: Humana Press, 1998.
19. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
20. Zukiwski, A., Gutterman, J., Bui, C., Sella, A., Ellerhorst, J., Tu, S., Amato, R., Figg, W., Kilbourn, R., and Logothetis, C. Phase I trial of the angiogenesis inhibitor TNP-470 (AGM-1470) in patients with androgen-independent prostate cancer. Proc. Am. Soc. Clin. Oncol., 13: 252, 1994.
21. Ong, V. S., Stamm, G. E., Menacherry, S., and Chu, S. Quantitation of TNP-470 and its metabolites in human plasma: sample handling, assay performance and stability. J. Chromatogr. B. Biomed. Sci. Appl., 710: 173-182, 1998.
22. Moore, J., and Sommadossi, J. P. Determination of O- (chloroacetylcarbamoyl) fumagillol (TNP-470; AGM-1470) and 2 metabolites in plasma by high-performance liquid-chromatography mass-spectrometry with atmospheric-pressure chemical-ionization. J. Mass Spectrometry, 30: 1707-1715, 1995.
23. Baker, W. J., Royer, G. L., Jr., and Weiss, R. B. Cytarabine and neurologic toxicity. J. Clin. Oncol., 9: 679-693, 1991.
24. Moertel, C., Reitemeier, R., Bolton, C., and Shorter, R. Cerebellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemother. Rep., 41: 15, 1964.
25. Curtin, J. P., Koonings, P. P., Gutierrez, M., Schlaerth, J. B., and Morrow, C. P. Ifosfamide-induced neurotoxicity. Gynecol. Oncol. 42: 193-196, 1991.
26. Dezube, B., Von Roenn, J., Holden-Wiltse, J., Cheung, T., Remick, S., Cooley, T., Moore, J., Sommadossi, J. P., Shriver, S., Suckow, C., and Gill, P. Fumagillin analogue in the treatment of Kaposi's sarcoma: a Phase I AIDS Clinical Trial Group study. J. Clin. Oncol., 16: 1444-1449, 1998.
27. Placidi, L., Cretton-Scott, E., de Sousa, G., Rahmani, R., Placidi, M., and Sommadossi, J. P. Disposition and metabolism of the angiogenic moderator O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) in human hepatocytes and tissue microsomes. Cancer Res., 55: 3036-3042, 1995.
28. Cretton-Scott, E., Placidi, L., McClure, H., Anderson, D. C., and Sommadossi, J. P. Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470) in rhesus monkeys. Cancer Chemother. Pharmacol., 38: 117-122, 1996.
29. Figg, W. D., Pluda, J. M., Lush, R. M., Saville, M. W., Wyvill, K., Reed, E., and Yarchoan, R. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy, 17: 91-97, 1997.
30. Stadler, W., Shapiro, C., Sossman, J., Clark, J., Vogelzang, N., and Kuzel, T. A multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol., 17: 310A, 1998.
31. Castronovo, V., and Belotti, D. TNP-470 (AGM-1470): mechanisms of action and early clinical development. Eur. J. Cancer, 32A: 2520-2527, 1996.